Specijalna Bolnica Medico

At Specijalna Bolnica Medico in Rijeka, clinical research in Dermatology centers on inflammatory and immune-driven skin conditions, with studies aimed at testing new treatments and improving symptom control for patients.

• Atopic dermatitis and alopecia areata
• Hidradenitis suppurativa, prurigo nodularis, and chronic spontaneous urticaria
• Bullous pemphigoid, cutaneous squamous cell carcinoma, and other difficult-to-treat skin diseases

These trials are focused on evaluating the safety and effectiveness of emerging therapies, with an emphasis on reducing inflammation, easing itching, and improving long-term disease control.

The site also supports a strong portfolio in digestive system diseases, especially inflammatory bowel disease, where researchers are assessing new options to better manage chronic intestinal inflammation.

• Crohn’s disease and ulcerative colitis
• Moderately to severely active Crohn’s disease and moderate to severe ulcerative colitis
• Studies of treatment response and endoscopic improvement

This research is designed to compare novel therapies with established care and to improve both disease control and patient quality of life.

In the area of respiratory tract diseases, clinical trials at this Croatia site include both chronic lung conditions and advanced cancers, reflecting a broad effort to improve outcomes in serious breathing-related illnesses.

• Non-small cell lung cancer and advanced lung cancer
• Chronic obstructive pulmonary disease, asthma, and bronchiectasis
• Testing new therapies and evaluating better disease control in complex pulmonary disorders

The studies aim to expand treatment choices, support symptom relief, and assess whether newer approaches can improve effectiveness in both cancer and chronic respiratory disease.

Cardiovascular diseases and related metabolic conditions are another important focus, with trials examining ways to prevent major events and improve care for patients with heart and vascular risk factors.

• Chronic heart failure and heart failure with preserved or mildly reduced ejection fraction
• Primary prevention of atherosclerotic cardiovascular disease and hypertension
• Type 2 diabetes with established cardiovascular disease

These trials are mainly evaluating whether new therapies can lower cardiovascular risk, reduce complications, and support better long-term disease management.

The research portfolio also includes immune system diseases and other inflammatory conditions, showing interest in how targeted therapies may help patients with complex autoimmune and kidney disorders.

• Systemic lupus erythematosus, antiphospholipid syndrome, and Behçet’s syndrome
• IgA nephropathy and immune thrombocytopenia
• Dermatomyositis, immune-mediated necrotizing myopathy, and other autoimmune diseases

The main goal of these studies is to assess safety, reduce inflammation, and determine whether newer treatments can provide more effective disease control.

Across neoplasms, the site participates in studies that explore new cancer treatments, especially for advanced solid tumors where improved options are still needed.

• Melanoma and cutaneous squamous cell carcinoma
• Non-small cell lung cancer and renal cell carcinoma
• Evaluating targeted therapies and combination approaches for better cancer control

This work focuses on testing whether emerging cancer therapies can improve effectiveness, safety, and outcomes in patients with advanced disease.